Therapeutic Asset Ratings
234 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
5-ala
Glioblastoma
Alpheus Medical, Inc.
P3
B
(58)
Chloroquine
Glioblastoma
Maastricht Radiation Oncology
P3
B
(58)
FLUOROURACILUM
Glioblastoma
Leaf Vertical Inc.
P3
B
(58)
Dasatinib
Glioblastoma
AHS Cancer Control Alberta
P2
B
(58)
Metformin
Glioblastoma
Weill Medical College of Cornell University
P2
B
(58)
Polyiclc
Glioblastoma
Jonsson Comprehensive Cancer Center
P2
B
(58)
azd1390
Glioblastoma
Children's Oncology Group
P2/3
B
(58)
Disulfiram
Glioblastoma
Olympion Medical Center
P2/3
B
(58)
Tinostamustine
Glioblastoma
Mundipharma Research Limited
P2/3
B
(58)
Veliparib
Glioblastoma
National Cancer Institute (NCI)
P2/3
B
(58)
Temsirolimus
Glioblastoma
Nader Sanai
P2
B
(57)
Copper
Glioblastoma
Olympion Medical Center
P2/3
B
(57)
Dabrafenib
Glioblastoma
National Cancer Institute (NCI)
P4
B
(56)
Abemaciclib
Glioblastoma
Tango Therapeutics, Inc.
P2
B
(56)
Cetuximab
Glioblastoma
University of Miami
P2
B
(56)
FIBROMUN
Glioblastoma
Philogen S.p.A.
P2
B
(56)
Fluciclovine
Glioblastoma
Abramson Cancer Center at Penn Medicine
P2
B
(56)
gw786034
Glioblastoma
Center Trials & Treatment
P2
B
(56)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Glioblastoma
National Cancer Institute (NCI)
P2
B
(56)
Letrozole
Glioblastoma
Nationwide Children's Hospital
P2
B
(56)
LEUPROLIDE
Glioblastoma
Nationwide Children's Hospital
P2
B
(56)
Olaparib
Glioblastoma
Fundación de investigación HM
P2
B
(56)
Palbociclib
Glioblastoma
AHS Cancer Control Alberta
P2
B
(56)
Ribociclib
Glioblastoma
Nationwide Children's Hospital
P2
B
(56)
Selinexor
Glioblastoma
National Cancer Institute (NCI)
P2
B
(56)
Showing 26 to 50 of 234 assets
Previous
Page 2 of 10
Next